.Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA09_Faricimab.Faricimab .Pharmacolibrary.Drugs.S_SensoryOrgans.S01L_OcularVascularDisorderAgents.S01LA09_Faricimab.Faricimab| name: | Faricimab |
| ATC code: | S01LA09 | route: | intravitreal |
| n-compartments | 2 |
Faricimab is a bispecific monoclonal antibody designed to bind and inhibit both angiopoietin-2 (Ang-2) and vascular endothelial growth factor A (VEGF-A). It is used for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). Faricimab was approved by the US FDA in 2022 and is currently in clinical use.
PK parameters reported in patients with neovascular age-related macular degeneration (nAMD) receiving a 6 mg intravitreal dose.
Diack, C, et al., & Cosson, V (2024). Ocular Pharmacokinetics of Faricimab Following Intravitreal Administration in Patients With Retinal Disease. Translational vision science & technology 13(11) 14–None. DOI:10.1167/tvst.13.11.14 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39535744
Diack, C, et al., & Bogman, K (2024). Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema. Translational vision science & technology 13(11) 13–None. DOI:10.1167/tvst.13.11.13 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39535745